首页> 美国卫生研究院文献>Scientific Reports >(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats
【2h】

(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats

机译:(S)-奥拉西坦是奥拉西坦中的活性成分可减轻大鼠慢性脑灌注不足引起的认知障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic cerebral hypoperfusion is a pathological state that is associated with the cognitive impairments in vascular dementia. Oxiracetam is a nootropic drug that is commonly used to treat cognitive deficits of cerebrovascular origins. However, oxiracetam is currently used as a racemic mixture whose effective ingredient has not been identified to date. In this study, we first identified that (S)-oxiracetam, but not (R)-oxiracetam, was the effective ingredient that alleviated the impairments of spatial learning and memory by ameliorating neuron damage and white matter lesions, increasing the cerebral blood flow, and inhibiting astrocyte activation in chronic cerebral hypoperfused rats. Furthermore, using MALDI-MSI and LC-MS/MS, we demonstrated that (S)-oxiracetam regulated ATP metabolism, glutamine-glutamate and anti-oxidants in the cortex region of hypoperfused rats. Altogether, our results strongly suggest that (S)-oxiracetam alone could be a nootropic drug for the treatment of cognitive impairments caused by cerebral hypoperfusion.
机译:慢性脑灌注不足是一种与血管性痴呆认知障碍有关的病理状态。奥拉西坦是一种促智药物,通常用于治疗脑血管起源的认知缺陷。但是,奥拉西坦目前用作外消旋混合物,其有效成分迄今尚未确定。在这项研究中,我们首先确定(S)-奥拉西坦,但不是(R)-奥拉西坦,是通过减轻神经元损伤和白质损伤,增加脑血流量来减轻空间学习和记忆障碍的有效成分,并抑制慢性脑灌注不足大鼠星形胶质细胞的活化。此外,使用MALDI-MSI和LC-MS / MS,我们证明了(S)-奥拉西坦调节了低灌注大鼠皮质区域的ATP代谢,谷氨酰胺-谷氨酸和抗氧化剂。总体而言,我们的结果强烈表明,仅(S)-奥拉西坦可能是一种促智药物,可用于治疗由脑灌注不足引起的认知障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号